N-{2-(benzylthio)-6-[((1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyl)amino]pyrimidin-4-yl}methanesulfonamide | 654072-60-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-{2-(benzylthio)-6-[((1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyl)amino]pyrimidin-4-yl}methanesulfonamide
• 英文别名: N-{2-(Benzylthio)-6-[((1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyl)amino]-pyrimidin-4-yl}methanesulfonamide；N-[2-benzylsulfanyl-6-[[(2R)-1-[tert-butyl(dimethyl)silyl]oxypropan-2-yl]amino]pyrimidin-4-yl]methanesulfonamide
• CAS: 654072-60-3
• 化学式: C₂₁H₃₄N₄O₃S₂Si
• 分子量: 482.743
• InChiKey: ZKKDQDDPURCBNF-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.96
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-{2-(benzylthio)-6-[((1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyl)amino]pyrimidin-4-yl}methanesulfonamide 在 N-氯代丁二酰亚胺 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-(2-(benzylthio)-5-chloro-6-{[(1R)-2-hydroxy-1-methylethyl]amino}pyrimidin-4-yl)methanesulfonamide
  参考文献：
  名称：

  [EN] PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
  [FR] MODULATEURS DU RECEPTEUR DE LA CHIMIOKINE A BASE DE DERIVES AMIDES DE PYRIMIDYL-SULFONE

  摘要：

  一种具有化学式（I）的化合物，其药用盐、溶剂合物或体内可水解酯，用于治疗哮喘、过敏性鼻炎、慢性阻塞性肺病（COPD）、炎症性肠病、肠易激综合征、骨关节炎、骨质疏松症、类风湿性关节炎、牛皮癣或癌症。

  公开号：

  WO2004011443A1
• 作为产物：
  描述：

  6-氨基-2-(苄基硫基)-4(3H)-嘧啶酮 在 potassium carbonate 、 N,N-二甲基苯胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-{2-(benzylthio)-6-[((1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethyl)amino]pyrimidin-4-yl}methanesulfonamide
  参考文献：
  名称：

  Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists

  摘要：

  Antagonism of the chemokine receptor CXCR2 has been proposed as a strategy for the treatment of inflammatory diseases such as arthritis, chronic obstructive pulmonary disease and asthma. Earlier series of bicyclic CXCR2 antagonists discovered at AstraZeneca were shown to have low solubility and poor oral bioavailability. In this Letter we describe the design, synthesis and characterisation of a new series of monocyclic CXCR2 antagonists with improved solubility and good pharmacokinetic profiles. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.067

文献信息

• Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
  申请人：Ebden Richard Mark

  公开号：US20060025432A1

  公开（公告）日：2006-02-02

  A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

  化合物(I)的配方，其药用盐、溶剂或体内可水解酯，用于治疗哮喘、过敏性鼻炎、慢性阻塞性肺疾病、炎症性肠病、肠易激综合症、骨关节炎、骨质疏松症、类风湿性关节炎、牛皮癣或癌症。
• [EN] PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR DE LA CHIMIOKINE A BASE DE DERIVES AMIDES DE PYRIMIDYL-SULFONE
  申请人：ASTRAZENECA AB

  公开号：WO2004011443A1

  公开（公告）日：2004-02-05

  A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.

  一种具有化学式（I）的化合物，其药用盐、溶剂合物或体内可水解酯，用于治疗哮喘、过敏性鼻炎、慢性阻塞性肺病（COPD）、炎症性肠病、肠易激综合征、骨关节炎、骨质疏松症、类风湿性关节炎、牛皮癣或癌症。
• Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists
  作者：Rupert P. Austin、Colin Bennion、Roger V. Bonnert、Lal Cheema、Anthony R. Cook、Rhona J. Cox、Mark R. Ebden、Alasdair Gaw、Ken Grime、Premji Meghani、David Nicholls、Caroline Phillips、Neal Smith、John Steele、Jeffrey P. Stonehouse

  DOI：10.1016/j.bmcl.2015.01.067

  日期：2015.4

  Antagonism of the chemokine receptor CXCR2 has been proposed as a strategy for the treatment of inflammatory diseases such as arthritis, chronic obstructive pulmonary disease and asthma. Earlier series of bicyclic CXCR2 antagonists discovered at AstraZeneca were shown to have low solubility and poor oral bioavailability. In this Letter we describe the design, synthesis and characterisation of a new series of monocyclic CXCR2 antagonists with improved solubility and good pharmacokinetic profiles. (C) 2015 Elsevier Ltd. All rights reserved.